CFDE Data Portal | Search RASAL2-AS1

	Label	Description
	RASAL2-AS1 associations Collection (Entity type)	Associations for RASAL2-AS1_associations
	RASAL2-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	RASAL2-AS1 Gene (Entity type)	ENSG00000224687 - RASAL2 antisense RNA 1
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE199107 tryptophan 6 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE229973 3 V 2 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS

RASAL2-AS1 associations

Associations for RASAL2-AS1_associations

RASAL2-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

RASAL2-AS1

ENSG00000224687 - RASAL2 antisense RNA 1

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

A Gene Set from LINCS

GSE199107 tryptophan 6 v 7 human up

A Gene Set from LINCS

GSE229973 3 V 2 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE205976 GSE205978 CEP83 knockout TIME 1 v 4 human dn

A Gene Set from LINCS

GSE48812 sulforaphane 4 v 10 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.